Global Bladder Cancer Market – Overview
The bladder cancer market is expected to grow at CAGR of 4.6% to reach USD 7.63 billion during the forecast period, 2022–2030.
The global Bladder Cancer Market Size is growing at a steady pace. This can be attributed to increasing prevalence of bladder cancer. It is reported that the exact cause of the bladder cancer is not clear, however, the medical condition is estimated to be acquainted with certain factors which are inclusive mutations in the genetic composition of the patients, continuous exposure to harmful radiations, and adoption of unhealthy lifestyle. Such conditions are responsible for increasing the reported cases of bladder cancer across the globe. Moreover, factors such as increasing government support along with the growing investment in the research and development process boosts the market growth. Additionally, rising awareness regarding the medical condition among the masses also contributes to the market growth. However, there factors such as high cost of the treatment in terms of expensive drugs, and related side effects are estimated to restrain the market growth during the projected period.
Bladder Cancer Market Overview By Type (Transitional Cell Carcinoma, Invasive Bladder Cancer), by Treatment (Chemotherapy, Radiation Therapy, Immunotherapy), by Diagnosis (Urine Lab Tests, Imaging Test), by End-User (Hospital, Clinic)
The global Bladder Cancer Market Players such as, Oncogenex (US), Astellas (Japan), Eli Lilly and Company (US), AstraZeneca (UK), F. Hoffmann-La Roche (Switzerland), GlaxoSmithKline (UK), Accord Healthcare, Inc.(India), Pfizer (US), Novartis AG (Switzerland) Bristol-Myers Squibb company (US) and others. These are some of the major market players at the forefront of competition in the global bladder cancer market.
· By type, the global bladder cancer market has been segmented into transitional cell bladder cancer, invasive bladder cancer, superficial bladder cancer, squamous cell bladder cancer, adenocarcinoma, and others.
· By treatment, the bladder cancer market is segmented into chemotherapy, immunotherapy, radiation therapy, surgery, and others.
· By end-user, the bladder cancer market is segmented into hospitals, clinics, cancer care centers, and others.
· By diagnosis, the global bladder cancer market has been segmented into urine lab tests, cystoscopy, biopsy, imaging tests, and others. The urine lab tests are classified into urinalysis, urine cytology, urine culture, and urine tumor marker test. The imaging test is further divided into Intravenous Pyelogram (IVP), Computed Tomography (CT) scan, Magnetic Resonance Imaging (MRI) scan, and bladder ultrasound.
Global Bladder Cancer Market Share- Competitive Analysis
The Bladder Cancer Market Research is well established market with number of companies operating in this market.
Bladder Cancer Market is expected to grow in the presence of increasing demands for better therapeutics. Currently, the market is witnessing an unavailability of absolute treatment. This can be seen as an for the market players to expand their market. The players, present in the global bladder cancer market are focusing on the development of new products. Such novel products are being designed with views of cost effectiveness and minimum side effects. Therefore, many companies in the market are involved in the development of specific types of molecules, and novel therapies have adopted the strategies of the acquisitions, product launches in order to strive in the competitive market. Additionally, competition amongst new entrants is expected to increase the growth for Bladder Cancer Market Report over the forecasted period.
In October 2017, Astellas and Seattle Genetics initiated pivotal trial of Enfortumab Vedotin for patients with locally advanced or metastatic urothelial cancer.
In May 2017, AstraZeneca plc received U.S. FDA accelerated approval for the drug Imfinzi (durvalumab). This drug is intended to be used for previously treated patients with advanced bladder cancer.
In February 2017, Bristol-Myers Squibb received the FDA approval for Opdivo (nivolumab) in previously treated locally advanced or metastatic urothelial carcinoma, a type of bladder cancer.
In April 2017, FDA granted Roche’s atezolizumab, an accelerated approval as an initial treatment procedure for treating patients with advanced bladder cancer. It is the only immunotherapy paradigm approved for the treatment of advanced bladder cancer.
In May 2017, Eli Lily & company announced results of their drug Cyramza’s phase III clinical trial for Bladder cancer. According to company reports, around 531 patients with urothelial carcinoma were treated in the trial, with a statistically significant improvement in progression-free survival. With this, Company received huge boost for the development of this drug in the treatment of bladder cancer.
In May 2017, FDA granted BAVENCIO (avelumab) approval for a common type of advanced bladder cancer.
Global Bladder Cancer Market - Regional Analysis
On the basis of the geography, the global Bladder Cancer Market Insights is segmented into the four major regions, namely the Americas, Europe, Asia Pacific, and the Middle East & Africa.
The Americas holds the largest share in the global bladder cancer market. Presence of huge patient population suffering from bladder cancer is a major reason behind the same. As per the American Cancer Society, approximately 79,030 new cases of bladder cancer were reported in 2017. Moreover, it was estimated that the disease caused about 16,870 deaths withihn the U.S. Additionally, factors includfing changing lifestyle, rising government support, incrteasing role of cancer care organisations for incraesing the awareness s also impacts a positive growth in the global bladder cancer market.
Europe accounts for the second largest market share for the bladder cancer, which is followed by Asia Pacific. Asia Pacific is the fastest growing market owing to the huge population base, increasing prevalence of bladder cancer, rapidly developing economies and presence of huge opportunity for the growth of the market. The Middle East & Africa has the least market share due to the unavailability of the required healthcare infrastructure, lack of awareness among people, and affordability issues due to presence of the poor economies in Africa region.
Market Research Future (MRFR) enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Market Research Future (part of Wantstats Research and Media Private Limited),
99 Hudson Street,5Th Floor, New York,
New York 10013